Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

The Only Tears From TearLab Are Tears Of Joy For Now

Some day I'll learn to buy the shares of the med-tech stocks I really like before I write them up for Seeking Alpha. Emerging eye care diagnostic company TearLab (NASDAQ:TEAR) was already on its way up when I wrote on the company in March of this year, but the stock has gone on for a further gain of about 66% since then, and it's hard to beat that sort of performance.

In the meantime, nothing has changed to dull my enthusiasm for the stock other than to say that the sharp move up has blunted some of the long-term potential from here. TearLab continues to book orders literally faster than they can fulfill them, and the margin leverage...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details